Loading…
Loading…
TLIS (Talis Biomedical Corporation) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
TLIS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TLIS and 80,000+ other tickers.
See exactly how TLIS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TLIS and 80,000+ other tickers.
Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologies for infectious diseases. The company currently provides the Talis One COVID-19 Test System, which is specifically designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond this, Talis is also developing a range of Talis One assay kits to target respiratory infections, infections related to women's health, and sexually…
Talis Biomedical Co. (NASDAQ: TLIS - Get Free Report)'s stock price traded up 77.5% during mid-day trading on Thursday. The stock traded as high as $2.84 and last traded at $2.84. 59,306 shares traded hands during mid-day trading, an increase of 2,761% from the average session volume of 2,073 shares. The stock had previously closed
Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon Closing; To Also Get up to $150M in Contingent Cash Upon Satisfaction of Condition; Proceeds Will Strengthen Balance Sheet and Support Growth Plans in the Vicuña District Expected Major Events for Monday aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 00:01/UK: Nov KPMG and REC UK Report on Jobs 04:30/JPN: Nov Corporate Insolvencies 05:00/JPN: Nov Economy Watchers Survey 07:00/GER: 3Q Labour cost index 15:00/US: Oct Monthly Wholesale Trade 15:00/US: Nov Employment Trends Index 23:50/JPN: Nov Money Stock, Broadly-defined Liquidity All times in GMT. Powered by Kantar Media and Dow Jones. Expected Earnings for Monday Amtech Systems Inc (ASYS) is expected to report $-0.01 for 4Q. Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials is expected to report for 4Q. Braze Inc (BRZE) is expected to report $-0.30 for 3Q. Buckle Inc (BKE) is expected to report. C3.ai Inc (AI) is expected to report $-0.60 for 2Q. Casey's General Stores Inc (CASY) is expected to report $4.25 for 2Q. Centene Corp (CNC) is expected to report for Full year. Digital Ally Inc (DGLY) is expected to report for 3Q. Franklin Resources Inc (BEN) is expected to report. Genasys Inc (GNSS) is expected to report $-0.11 for 4Q. Healthequity Inc (HQY) is expected to report $0.24 for 3Q. MongoDB Inc (MDB) is expected to report $-0.83 for 3Q. NexPoint Diversified Real Estate Trust (NXDT) is expected to report for 3Q. North West Co Inc (NWC.T) is expected to report $0.77 for 3Q. Oil-Dri Corp of America (ODC) is expected to report for 1Q. Oracle Corp (ORCL) is expected to report $1.06 for 2Q. Phreesia Inc (PHR) is expected to report $-0.27 for 3Q. Planet Labs PBC (PL) is expected to report $-0.08 for 3Q. Remark Holdings Inc (MARK) is expected to report $-0.19 for 3Q. Rent the Runway Inc (RENT) is expected to report for 3Q. Smart Share Global Ltd - ADR (EM) is expected to report for 3Q. Talis Biomedical Corp (TLIS) is expected to report for 3Q. Titan Pharmaceuticals Inc (TTNP) is expected to report for 3Q. Toll Brothers Inc (TOL) is expected to report $4.34 for 4Q. Vail Resorts (MTN) is expected to report $-4.96 for 1Q. VersaBank is expected to report $0.29 for 4Q. Webco Industries Inc (WEBC) is expected to report for 1Q. Yext Inc (YEXT) is expected to report $0.06 for 3Q. Powered by Kantar Media and Dow Jones. ANALYST RATINGS ACTIONS Altria Raised to Buy From Neutral by B of A Securities Argan Cut to Market Perform From Market Outperform by CJS Securities Asana Raised to Sector Weight From Underweight by Keybanc Brixmor Property Group Raised to Outperform From Market Perform by BMO Capital Deere & Co Cut to Hold From Buy by Jefferies DocuSign Cut to Reduce From Hold by HSBC Dollar General Raised to Buy From Underperform by B of A Securities Duckhorn Portfolio Cut to Hold From Buy by Jefferies EPAM Systems Raised to Buy From Neutral by Goldman Sachs Fortrea Holdings Cut to Neutral From Outperform by Baird GrafTech International Raised to Neutral From Underweight by JP Morgan Hewlett Packard Ent Raised to Buy From Neutral by Citigroup Kennametal Cut to Hold From Buy by Jefferies Molson Coors Beverage Raised to Buy From Neutral by B of A Securities ONE Gas Cut to Neutral From Buy by Ladenburg Thalmann Paccar Cut to Hold From Buy by Jefferies Peloton Interactive Raised to Neutral From Sell by UBS PJT Partners Raised to Neutral From Sell by UBS PotlatchDeltic Raised to Outperform From Market Perform by BMO Capital ProFrac Holding Cut to Underweight From Neutral by JP Morgan Prologis Cut to Underperform From Market Perform by BMO Capital ProPetro Holding Raised to Neutral From Underweight by JP Morgan Republic Services Raised to Outperform From Market Perform by BMO Capital Robinhood Markets Raised to Buy From Neutral by Goldman Sachs SiteOne Landscape Supply Raised to Buy From Hold by Jefferies Smith & Wesson Brands Cut to Hold From Buy by Craig-Hallum Smith & Wesson Brands Cut to Hold From Buy by Lake Street Timken Raised to Buy From Hold by Jefferies WesBanco Raised to Strong Buy From Outperform by Raymond James Weyerhaeuser Raised to Outperform From Market Perform by BMO Capital This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires 12-09-24 0634ET
Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.
Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel.